JP2011506308A - 冬虫夏草菌糸体抽出物を有効成分として含む移植片拒絶抑制用組成物 - Google Patents
冬虫夏草菌糸体抽出物を有効成分として含む移植片拒絶抑制用組成物 Download PDFInfo
- Publication number
- JP2011506308A JP2011506308A JP2010536829A JP2010536829A JP2011506308A JP 2011506308 A JP2011506308 A JP 2011506308A JP 2010536829 A JP2010536829 A JP 2010536829A JP 2010536829 A JP2010536829 A JP 2010536829A JP 2011506308 A JP2011506308 A JP 2011506308A
- Authority
- JP
- Japan
- Prior art keywords
- cordyceps
- composition
- mycelium extract
- present
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000190633 Cordyceps Species 0.000 title claims abstract description 68
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 206010052779 Transplant rejections Diseases 0.000 title claims abstract description 15
- 239000004480 active ingredient Substances 0.000 title claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 238000002054 transplantation Methods 0.000 claims abstract description 27
- 208000017520 skin disease Diseases 0.000 claims abstract description 16
- 210000000056 organ Anatomy 0.000 claims abstract description 15
- 241000700647 Variola virus Species 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 241000721454 Pemphigus Species 0.000 claims abstract description 9
- 206010003645 Atopy Diseases 0.000 claims abstract description 6
- 206010011985 Decubitus ulcer Diseases 0.000 claims abstract description 6
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 230000001506 immunosuppresive effect Effects 0.000 claims description 13
- 206010062016 Immunosuppression Diseases 0.000 claims description 6
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 6
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 claims description 2
- 244000184734 Pyrus japonica Species 0.000 claims description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 1
- 235000017491 Bambusa tulda Nutrition 0.000 claims 1
- 241001264174 Cordyceps militaris Species 0.000 claims 1
- 241000578422 Graphosoma lineatum Species 0.000 claims 1
- 241001248589 Hymenostilbe odonatae Species 0.000 claims 1
- 240000001307 Myosotis scorpioides Species 0.000 claims 1
- 241000005785 Ophiocordyceps nutans Species 0.000 claims 1
- 241000357411 Ophiocordyceps tricentri Species 0.000 claims 1
- 244000082204 Phyllostachys viridis Species 0.000 claims 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 1
- 239000011425 bamboo Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 13
- 230000037396 body weight Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 229960003444 immunosuppressant agent Drugs 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 230000001861 immunosuppressant effect Effects 0.000 abstract description 5
- 208000030961 allergic reaction Diseases 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000004989 spleen cell Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 229940125721 immunosuppressive agent Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002547 new drug Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001248592 Isaria japonica Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- -1 olive oil Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091085748 Bat family Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
天然痘モデルマウス(慶応大学医学部微生物学・免疫学教室から得た)を用いて本発明による冬虫夏草菌糸体抽出物の免疫抑制実験を行なった。
本発明による冬虫夏草菌糸体抽出物の、天疱瘡モデルマウスに対する免疫抑制効果実験を以下のように行なった。
1−1.散剤の製造
−冬虫夏草菌糸体抽出物 1g
−デキストリン 0.1g
前記成分を混合して気密包に充填して散剤を製造した。
−冬虫夏草菌糸体抽出物 500mg
−デキストリン 45mg
−ステアリン酸マグネシウム 5mg
前記成分を混合した後、通常の錠剤の製造方法にしたがって錠剤を製造した。
−冬虫夏草菌糸体抽出物 500mg
−デキストリン 50mg
前記成分を混合した後、通常のカプセル剤の製造方法にしたがってゼラチンカプセルに充填してカプセル剤を製造した。
−冬虫夏草菌糸体抽出物 50mg/ml
−薄い塩酸BP pH3.5になるまで添加
−注射用塩化ナトリウムBP 最大1ml
適当な体積の注射用塩化ナトリウムBP中に冬虫夏草菌糸体抽出物を溶解させて、生成された溶液のpHを薄い塩酸BPを使用してpH3.5に調節し、注射用塩化ナトリウムBPを使用して体積を調節して充分に混合した。溶液を透明な5mlタイプIアンプル中に充填し、溶解させることで密封し、120℃で15分オートクレーブして注射液剤を製造した。
Claims (7)
- 冬虫夏草菌糸体抽出物を有効成分として含む、移植片拒絶の抑制のための免疫抑制用組成物。
- 前記冬虫夏草が、ミリタリス冬虫夏草(Cordyceps militaris)、シネンシス冬虫夏草(Cordyceps sinensis)、ヤンマタケ(Hymenostilbe odonatae)、カメムシタケ(Cordyceps nutans)、オサムシタケ(Tilachlidiopsis nigra)、雪花冬虫夏草(Paecilomyces japonica)、アワフキムシタケ(Cordyceps tricentri)および蜂冬虫夏草(Cordyceps sphecocephala)からなる群から選択されるいずれかひとつである、請求項1に記載の免疫抑制用組成物。
- 経口投与、静脈内投与または腹腔内投与されるのに適した投与形態である、請求項1に記載の免疫抑制用組成物。
- 経口投与時の投与量が、一日あたり550〜2,200mgである、請求項3に記載の免疫抑制用組成物。
- 臓器または組織移植後の移植片拒絶を起こす抗体の生成を抑制する、請求項1に記載の免疫抑制用組成物。
- 冬虫夏草菌糸体抽出物を有効成分として含む、皮膚疾患の予防及び治療用組成物。
- 前記皮膚疾患が、アトピー、蓐瘡、天疱瘡および/または天然痘である、請求項6に記載の組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2007/006356 WO2009072688A1 (en) | 2007-12-07 | 2007-12-07 | Composition for inhibition of trasplant rejection containing the cordyceps mycellia extract as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011506308A true JP2011506308A (ja) | 2011-03-03 |
JP5872769B2 JP5872769B2 (ja) | 2016-03-01 |
Family
ID=40717857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010536829A Expired - Fee Related JP5872769B2 (ja) | 2007-12-07 | 2007-12-07 | 冬虫夏草菌糸体抽出物を有効成分として含む移植片拒絶抑制用組成物 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20100291154A1 (ja) |
JP (1) | JP5872769B2 (ja) |
KR (1) | KR101266527B1 (ja) |
WO (1) | WO2009072688A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015529670A (ja) * | 2012-09-13 | 2015-10-08 | 江中▲薬▼▲業▼股▲ふん▼有限公司 | 免疫を調節する漢方薬組成物及びその製造方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641339B (zh) * | 2012-04-25 | 2014-03-05 | 吉林大学珠海学院 | 一种提高机体免疫力、抗疲劳度的中药复方制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0940690A (ja) * | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
JPH09124501A (ja) * | 1995-10-26 | 1997-05-13 | Ajinomoto Co Inc | 新規免疫抑制剤 |
JP2005097192A (ja) * | 2003-09-25 | 2005-04-14 | Bio Solutions:Kk | 免疫力強化活性剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117118A (en) * | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
WO1996000580A1 (fr) * | 1994-06-30 | 1996-01-11 | Meiji Milk Products Company Limited | Composition favorisant la sante |
KR100544945B1 (ko) * | 2003-11-27 | 2006-01-24 | 박태선 | 밀리타리스동충하초 추출물을 유효성분으로 포함하는면역증진용 약학조성물 |
KR20060092373A (ko) * | 2005-02-17 | 2006-08-23 | (주)네오팜 | 소아 아토피 피부염의 예방 및 개선용 생약 조성물 |
US20100285053A1 (en) * | 2006-06-09 | 2010-11-11 | Dalhousie University | Immunosuppressive Extract Of Cordyceps Sinensis And Uses Thereof |
-
2007
- 2007-12-07 KR KR1020107016849A patent/KR101266527B1/ko active IP Right Grant
- 2007-12-07 JP JP2010536829A patent/JP5872769B2/ja not_active Expired - Fee Related
- 2007-12-07 WO PCT/KR2007/006356 patent/WO2009072688A1/en active Application Filing
- 2007-12-07 US US12/740,139 patent/US20100291154A1/en not_active Abandoned
-
2011
- 2011-06-16 US US13/161,958 patent/US8206760B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0940690A (ja) * | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
JPH09124501A (ja) * | 1995-10-26 | 1997-05-13 | Ajinomoto Co Inc | 新規免疫抑制剤 |
JP2005097192A (ja) * | 2003-09-25 | 2005-04-14 | Bio Solutions:Kk | 免疫力強化活性剤 |
Non-Patent Citations (8)
Title |
---|
JPN6012048644; J. Ethnopharmacol. Vol.83, 2002, pp.79-85 * |
JPN6012048645; Br. J. Pharmacol. Vol.140, 2003, pp.895-906 * |
JPN6012048647; Database on Medline AN 1996045174 * |
JPN6012048648; Chemical Abstracts AN 2005:269287 * |
JPN6012048650; Phytochemistry Vol.51, 1999, pp.891-898 * |
JPN6013026669; Nat. Prod. Sci. Vol.9 No.4, 2003, pp.291-298 * |
JPN6013026673; J. Appl. Microbiol. Vol.99, 2005, pp.728-738 * |
JPN6013026675; Biochim. Biophys. Acta Vol.41, 1960, pp.363-365 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015529670A (ja) * | 2012-09-13 | 2015-10-08 | 江中▲薬▼▲業▼股▲ふん▼有限公司 | 免疫を調節する漢方薬組成物及びその製造方法 |
US9775868B2 (en) | 2012-09-13 | 2017-10-03 | Jiangzhong Pharmaceutical Co., Ltd. | Traditional Chinese medicine combination for regulating immune function and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
US20110243970A1 (en) | 2011-10-06 |
WO2009072688A1 (en) | 2009-06-11 |
US8206760B2 (en) | 2012-06-26 |
KR20100112597A (ko) | 2010-10-19 |
KR101266527B1 (ko) | 2013-05-27 |
JP5872769B2 (ja) | 2016-03-01 |
US20100291154A1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020172523A (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び/又は刺激におけるその使用 | |
CN101380346B (zh) | 一种治疗肿瘤的中药组合物及其制作方法 | |
KR101395858B1 (ko) | 다당류 리포솜, 이의 제조 방법 및 용도 | |
JP6389958B2 (ja) | 瓦草5環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
TW201618801A (zh) | 用於輔助化療藥物之醫藥組合物及其用途 | |
JP5872769B2 (ja) | 冬虫夏草菌糸体抽出物を有効成分として含む移植片拒絶抑制用組成物 | |
CN105343056A (zh) | 一种治疗或预防肥胖型高血压的口服药物组合物及其用途 | |
WO2005077395A1 (ja) | 生理活性組成物及びその製造方法 | |
TWI379678B (ja) | ||
KR101989739B1 (ko) | 구슬갓냉이 추출물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 조성물 | |
EP0195870A1 (fr) | Utilisation de levures saccharomyces pour la fabrication d'un médicament contre l'amibiase | |
CN112891362B (zh) | 一种用于治疗脓毒症的药物组合物及其应用 | |
CN101757019B (zh) | 用于减肥或治疗代谢综合征的药物组合物 | |
JP2007031302A (ja) | アディポネクチン産生促進剤、及び代謝異常症候群予防剤 | |
KR101308142B1 (ko) | 상황버섯 균사체 추출물을 유효성분으로 함유하는 면역 억제용 조성물 | |
TW201808316A (zh) | 牛樟段木栽培牛樟芝子實體及固態培養菌絲體水及乙醇萃取物之組合物應用於抗癌藥輔助劑 | |
KR100824704B1 (ko) | 지실 추출물을 유효성분으로 함유하는 비만 치료 및 예방용조성물 | |
CN1305471C (zh) | 氧化槐定碱在制备抗癌药的用途 | |
KR20040087407A (ko) | 진세노사이드를 함유함을 특징으로 하는 면역증강효과에 대한 조성물 | |
KR102506076B1 (ko) | 황산아연, 락토바실러스 애시도필러스 및 코엔자임 q를 포함하는 면역질환의 예방 또는 치료용 조성물 | |
JP3195916B2 (ja) | Aidsにおけるヘルパーt細胞数の減少抑制若しくは増加剤 | |
RU2468802C2 (ru) | Комбинированная противотуберкулезная композиция | |
WO2000032214A1 (en) | Preventives for hepatopathy | |
KR20090019396A (ko) | 쥐눈이콩 물추출물을 포함하는 알레르기성 질환의 예방 및치료용 약학조성물 | |
KR20050045982A (ko) | 애매미유충눈꽃동충하초를 유효성분으로 하는 식품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130823 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140910 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140925 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20141128 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150603 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5872769 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |